Phase 1 Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People between 6 months and 30 years of age
• People whose brain tumour can be measured or assessed on at least two dimensions using MRI scans taken at the time of joining the trial
• People who have had imaging scans done within 14 days before starting treatment
• People with a functional ability score (a measure of how well someone can carry out daily activities) of at least 60 out of 100 on standard scales used for adults and children
• People who have recovered sufficiently from side effects of previous radiation or chemotherapy, meaning serious side effects have improved to a mild level, or if ongoing complications exist, the person is considered stable by their treating doctors
• People who have had a small device surgically placed in the brain to allow fluid access, along with a specific monitoring probe (confirm with trial site for exact device details)
• People (or their parents or legal guardians) who have given written, signed consent to participate. Children under 18 must have a parent or legal guardian provide consent. Children aged 7 and older will also be asked to give their own written agreement where appropriate
• People who are able to have their own immune cells collected to make the study treatment, and whose collected cells meet specific quality standards set by the laboratory
• People who are capable of having children and are willing to use birth control from the time of joining the trial and for four months after receiving the treatment
• Females who are capable of becoming pregnant must have a negative pregnancy test before joining

Who may not be able to join:

• Women who are pregnant or breastfeeding
• People with severe, uncontrolled active infections
• People with HIV, or active Hepatitis C (HCV) or Hepatitis B (HBV) infection
• People whose disease is progressing very rapidly and whose life expectancy is less than 6 weeks
• People who have had a severe allergic reaction (grade 3 or 4) to products containing mouse-derived proteins in the past
• People whose liver is not functioning adequately, based on specific blood test results being above set limits
• People whose kidneys are not functioning adequately, based on a specific blood test result being above the set limit for their age
• People whose blood oxygen level is below 90%
• People whose heart pumping function (measured by an ultrasound of the heart) is below 45%
• People whose blood counts are too low — specifically, a type of infection-fighting white blood cell count below 500/mm³, and/or platelet count below 20,000 (not achieved through a transfusion)
• People with heart failure, irregular heart rhythms, psychiatric illness, or personal or social circumstances that the lead investigator believes would make safe participation in the study too risky or make it difficult to follow study requirements
• People currently receiving steroid medications unless the dose has been stable or reducing for at least 7 days before treatment (inhaled, topical, or non-absorbed steroids are generally not excluded; confirm with trial site)
• People who have received systemic chemotherapy within 3 weeks before the planned treatment infusion
• People who have received immune-suppressing medications within the past 30 days
• People who have not completed radiation therapy at least 6 weeks before joining
• People who are currently receiving, or have received within the past 30 days, another experimental anti-cancer treatment
• People whose specially prepared immune cells (made from their own cells for this trial) do not meet the required quality and safety standards set by the laboratory

Important: Always verify eligibility with the trial site directly before applying.